HC Andersen Capital Events 29/03: Meet the top management in NNIT & Pharma Equity Group

HC Andersen Capital is hosting a digital event where you can meet and ask questions directly to the top management. It is free for all to attend.

NNIT - Presentation of annual report 2022
NNIT released its annual report on 23 March 2023. Meet NNIT’s management who will present the results followed by a Q&A session at a virtual live event.  

In 2022, NNIT grew its topline on its continuing business by 10% and experienced better growth in the second half of 2022 with most of the growth driven by acquisitions. In 2022, NNIT realized an operating loss (EBIT) of DKK 7m, which is a level that is still affected by the carve-out costs of the divested business.  

For 2023, NNIT expects revenue to grow by around 10% and realize an EBIT margin of approx. 5%. The latter is still influenced by the carve-out costs, especially seen in the light of the delayed divestment process. The closing of the divestment of the infrastructure business is now expected in Q2 2023 (instead of Q1 2023) due to a delayed FDI approval process with the Danish Business Authority.  

Disclaimer: HC Andersen Capital receives payment from NNIT for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis 09:38, 24 March 2023.

Wednesday 29th of March - 12.00-12.30

Sign up via. link


_______________________
This event is in Danish

Pharma Equity Group - Første handelsdag samt gennemgang af markedspotentiale
Mød og stil spørgsmål til kommende CEO Thomas Selsø, der blandt andet vil give en opdatering på hele processen til børsen samt første handelsdag. Derudover vil han fokusere på markedspotentialet for de enkelte lægemidler.  

Reponex Pharmaceuticals, som er en del af Pharma Equity Group, har fokus på repositionering af eksisterende API’er (Aktive farmaceutiske ingredienser) til andre indikationer. Pharma Equity Group erhverver en portefølje med 4 stk. kliniske fase 2 projekter i forbindelse med transaktionen. Alle 4 projekter er indenfor større sygdomsområder. Herunder bakteriel peritonitis (bughindebetændelse), kroniske hudsår, inflammatoriske tarmsygdomme samt tyk- og endetarmskræft  

Disclaimer: HC Andersen Capital modtager betaling fra Pharma Equity Group for en Digital IR/Corporate Visibility abonnementsaftale. /Claus Thestrup kl. 14:24, 22-03-2023.

Onsdag den 29. marts kl. 13:00 - 13:45

Tilmeld via. link


Disclaimer: HC Andersen Capital receives payment from the companies mentioned for a DigitalIR/Corporate Visibility agreement. The content is not buy or sell recommendations. 

Mie Halse
Head of Digital and Events
mie@hcandersencapital.dk
+45 28746640
 

HC Andersen Capital digitizes the relationship between listed companies and investors. We work long-term for companies that want more visibility in the market. #DemocraticIR - HC Andersen Capital works to democratize access to the financial market.